Table 1.
Results of landmark trials evaluating antiangiogenic agents in metastatic non-small-cell lung cancer.
| Study/phase | Chemotherapy | Number of patients (n) | ORR (%) | Median PFS (months) | HR (95% CI); p | Median OS (months) | HR (95% CI); p |
|---|---|---|---|---|---|---|---|
| ECOG 4599/phase III | Pac/Carbo | 444 | 15 | 4.5 | HR = 0.66 (0.57–0.77); p < 0.001 | 10.3 | HR = 0.79 (0.67–0.92); p = 0.003 |
| Pac/Carbo/Bev | 434 | 35 | 6.2 | 12.3 | |||
| AVAiL/phase III | Cis/Gem | 345 | 21.6 | 6.1 | –HR = 0.75 (0.64–0.87); p = 0.0003 | 13.1 | –HR = 0.93 (0.78–1.11); p = 0.420 |
| Cis/Gem/Bev | |||||||
| –7.5 mg/kg | –345 | –37.8 | –6.7 | –HR = 0.85 (0.73–1.00); p = 0.0456 | –13.6 | –HR = 1.03 (0.86–0.54); p < 0.01 | |
| –15 mg/kg | –351 | –34.6 | –6.4 | –13.4 | |||
| BEYOND/phase III | Pac/Carbo | 138 | 26 | 6.5 | HR = 0.40 (0.29–0.54); p < 0.01 | 17.7 | HR = 0.68 (0.50–0.93); p = 0.0154 |
| Pac/Carbo/Bev | 138 | 54 | 9.2 | 24.3 | |||
| AVAPERL/phase III | Cis/Pem/Bev | 376 | – | – | – | – | – |
| Pem/Bev maintenance | 128 | – | 7.4 | HR = 0.57 (0.44–0.75); p < 0.0001 | 17.1 | HR = 0.87 (0.63–1.21); p = 0.29 | |
| Bev maintenance | 125 | – | 3.7 | 13.2 | |||
| POINTBREAK/phase III | Carbo/Pem/Bev → Bev/Pem maintenance | 472 | 34 | 6 | HR = 0.83 (0.71–0.96); p = 0.012 | 13.4 | HR = 1.0 (0.86–1.16); p = 0.949 |
| Carbo/Pac/Bev → Bev maintenance | 467 | 33 | 5.6 | 12.6 | |||
| PRONOUNCE/phase III | Carbo/Pem → Pem | 182 | 23.6 | 4.44 | HR = 1.06 (0.84–1.35); p = 0.610 | 10.5 | HR = 1.07 (0.83–1.36); p = 0.615 |
| Carbo/Pac/Bev → Bev | 179 | 27.4 | 5.49 | 11.7 | |||
| JO25567/phase II | Erlotinib | 75 | 64 | 9.7 | HR = 0.54 (0.36–0.79); p = 0.0015 | – | – |
| Erlotinib/Bev | 77 | 69 | 16.0 | – | |||
| BELIEF/phase II | Erlotinib/Bev | 109 | – | 13.6 | – | – | – |
| All patients | 60 | 70.3 | 15.4 | – | |||
| T790M-mutated EGFR | |||||||
| REVELa/phase III | Docetaxel | 625 | 14 | 3.0 | HR = 0.76 (0.68–0.86); p < 0.0001 | 9.1 | HR = 0.86 (0.75–0.98); p = 0.023 |
| Docetaxel/ramucirumab | 628 | 23 | 4.5 | 10.5 | |||
| LUME-lung 1a/phase III | Docetaxel | 659 | 1.5 | 1.5 | HR = 0.63 (0.48–0.83); p = 0.0008 | 9.1 | HR = 0.94 (0.83–1.05); p = 0.2720 |
| Docetaxel/nintedanib | 655 | 4.9 | 3.6 | 10.1 | |||
| LUME-lung 2a/phase III | Pem | 360 | 8.3 | 3.6 | HR = 0.83 (0.70–0.99); p = 0.0435 | 12.7 | HR = 1.03 (0.85–1.21); p = 0.8940 |
| Pem/nintedanib | 353 | 9.1 | 4.4 | 12.2 | |||
HR, hazard ratio; PFS, progression free survival; OS, overall survival; Pac, paclitaxel; Carbo, carboplatin; Bev, bevacizumab; Cis, cisplatin; Gem, gemcitabine; Pem, pemetrexed; ECOG, Eastern Cooperative Oncology Group.
aTrials in the second-line setting.